<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>

<!-- This file generated using Python HTMLgen module. -->
<HEAD>
  <META NAME="GENERATOR" CONTENT="HTMLgen 2.2.2">
        <TITLE>Drug Interaction Knowledge Base 1.2</TITLE>

 <LINK rel=stylesheet href="html/HTMLgen.css" type="text/css" title="html/HTMLgen.css">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#0000FF" VLINK="#EE0000">
<span style="width: 60px"></span> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<H3>Drug Interaction Knowledge Base 1.2</H3>
<H2>aripiprazole_substrate_of_cyp2d6</H2>
<HR>

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>

<!-- This file generated using Python HTMLgen module. -->
<HEAD>
  <META NAME="GENERATOR" CONTENT="HTMLgen 2.2.2">
        <TITLE></TITLE>

 <LINK rel=stylesheet href="html/HTMLgen.css" type="text/css" title="html/HTMLgen.css">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#0000FF" VLINK="#EE0000">
<b>You can go to DIKB assertion index here:</b>  
<A HREF="/dikb-evidence/index.html">DIKB assertion index</A>
<br><b>You can go to DIKB the home page here:</b>  
<A HREF="/dikb-evidence/front-page.html">DIKB Front Page</A>

<P>

<a name="
aripiprazole_substrate_of_cyp2d6
"></a>
<b>Assertion:
aripiprazole substrate_of cyp2d6
</b>
<BR>
<A NAME="Evidence"></A>
<P><TABLE border=2 cellpadding=4 cellspacing=1 width="100%">
<CAPTION align=top><STRONG>Evidence</STRONG></CAPTION>
<TR><TD Align=left ><STRONG>Evidence For (item 0)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>Non_traceable_Drug_Label_Statement</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c040bd1d-45b7-49f2-93ea-aed7220b30ac</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG>Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism. Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.<br><br>Ketoconazole and Other CYP3A4 Inhibitors<br><br>Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of its normal dose. Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions; moderate inhibitors (erythromycin, grapefruit juice) have not been studied. When the CYP3A4 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased.<br><br>Quinidine and Other CYP2D6 Inhibitors<br><br>Coadministration of a 10 mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydro-aripiprazole, by 35%. Aripiprazole dose should be reduced to one-half of its normal dose when quinidine is given concomitantly with aripiprazole. Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and should lead to similar dose reductions. When the CYP2D6 inhibitor is withdrawn from the combination therapy, the aripiprazole dose should be increased. When adjunctive ABILIFY is administered to patients with Major Depressive Disorder, ABILIFY should be administered without dosage adjustment as specified in DOSAGE AND ADMINISTRATION (2.3).<br><br>Carbamazepine and Other CYP3A4 Inducers<br><br>Coadministration of carbamazepine (200 mg twice daily), a potent CYP3A4 inducer, with aripiprazole (30 mg/day) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole. When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from the combination therapy, the aripiprazole dose should be reduced.</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG></TD>
</TR>
<TR><TD Align=left ><STRONG>No evidence against!</STRONG></TD>
</TR>
</TABLE><P>

<BR>

</BODY> </HTML>

<b>You can go to DIKB assertion index here:</b>  
<A HREF="/dikb-evidence/index.html">DIKB assertion index</A>
<br><b>You can go to DIKB the home page here:</b>  
<A HREF="/dikb-evidence/front-page.html">DIKB Front Page</A>

<P>

<BR><BR><a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc-sa/3.0/88x31.png" /></a><br /><span xmlns:dct="http://purl.org/dc/terms/" href="http://purl.org/dc/dcmitype/Dataset" property="dct:title" rel="dct:type">Drug Interaction Knowledge Base (DIKB)</span> by <a xmlns:cc="http://creativecommons.org/ns#" href="http://www.dbmi.pitt.edu/person/richard-boyce-phd" property="cc:attributionName" rel="cc:attributionURL">Richard D. Boyce</a> is licensed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/3.0/">Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License</a>.

<P><HR>
<span style="width: 60px"></span> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<BR><IMG src="./images/logo.jpg" alt="logo.jpg" align="bottom">
<FONT SIZE="-1"><P>Copyright &#169 (c) 2005-2012 Richard David Boyce<BR>All Rights Reserved<BR>

Comments to author: <A HREF="mailto:&#114;d&#98;2&#48; &#97;t&#32;p&#105;t&#116; &#60;d&#111;t&#62; &#101;d&#117;">rdb20 at pitt <dot> edu</A><br>
Generated: Wed Jul 29, 2015 <BR><hr>
</FONT>
</BODY> </HTML>
